Not provided
Not provided
Not provided
Not provided
Not provided
Poor recruitment
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Birmingham | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Starter Group | Experimental | Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0. |
|
| Group A | Experimental | Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0. |
|
| Group B | Experimental | Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aerosol inhaled MVA85A | Biological |
|
| |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (AE) | Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months. | Up to Day 168 |
| Measure | Description | Time Frame |
|---|---|---|
| Laboratory Markers of Immunity | Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples. | Up to Day 168 |
Not provided
Inclusion Criteria:
Volunteers must meet all of the following criteria to enter the trial:
Exclusion Criteria:
Volunteers must meet none of the following criteria to enter the trial:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen McShane | University of Oxford | Study Director |
| Paul Moss | University of Birmingham | Principal Investigator |
| Marc Lipman | Royal Free Hostpital | Principal Investigator |
| Felicity Perrin | King's College Hospital NHS Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital | Oxford | Oxfordshire | OX3 7LE | United Kingdom | ||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Starter Group | Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0. |
| FG001 | Group A | Receive 5x10^7 pfu aerosol inhaled MVA85A |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Dec 19, 2017 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Intramuscular MVA85A |
| Biological |
|
|
| Intramuscular Saline placebo | Biological |
|
|
| Aerosol inhaled Saline placebo | Biological |
|
|
| John Warin Ward, Churchill Hospital |
| Oxford |
| Oxfordshire |
| OX3 7LE |
| United Kingdom |
| NIHR Wellcome Trust Clinical Research Facility, University of Birmingham | Birmingham | West Midlands | B15 2TH | United Kingdom |
| NIHR/Wellcome Trust King's Clinical Research Facility | London | United Kingdom |
| Royal Free Hospital NHS Foundation Trust | London | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Starter Group | Received 1x10^7 pfu aerosol inhaled MVA85A at day 0. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
| |||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Adverse Events (AE) | Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months. | Posted | Count of Participants | Participants | Up to Day 168 |
|
|
| |||||||||||||||||||||||||||
| Secondary | Laboratory Markers of Immunity | Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples. | Not Posted | Up to Day 168 | Participants |
All AEs occurring for 6 months following the vaccination that were observed by the investigator or reported by the volunteer, whether or not attributed to study medication, were recorded by volunteers on electronic diary cards or by staff on CRFs.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Starter Group | Received 1x10^7 pfu aerosol inhaled MVA85A at day 0. | 0 | 2 | 0 | 2 | 1 | 2 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| radiological changes | Investigations | MedDRA (Unspecified) | Systematic Assessment | transient asymptomatic radiological changes to the lung on CT scan at Day 28. |
|
Due to significant challenges with recruitment at all UK sites this study has been terminated early.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Professor Helen McShane | University of Oxford | +44 (0)1865 617606 | helen.mcshane@ndm.ox.ac.uk |
| Aug 12, 2020 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C549320 | MVA 85A |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided
| >=65 years |
|